ORKA · Nasdaq · CIK 0000907654

Oruka Therapeutics, Inc.

Oruka Therapeutics, Inc.’s most recent SEC filing in our snapshot is a Form 8-K filed on Oct 26, 2026. Its EDGAR record lists 55 Form 4 insider filings from the 12 months before our last refresh.

SEC EDGAR snapshot updated Oct 27, 2026, 11:27 PM EDT. See all filings on sec.gov.

Revenue, FY2025
—
Net income, FY2025
-$105.4M
Form 4 filings on record, past 12 months
55

Company overview

Legal name (as filed)
Oruka Therapeutics, Inc.
Ticker
ORKA
SEC Central Index Key (CIK)
0000907654
Industry (SIC)
Pharmaceutical Preparations (code 2834)
Business address
MENLO PARK, CA
State or country of incorporation
DE
Fiscal year ends
December 31
SEC filer category
Non-accelerated filer<br>Smaller reporting company
Position in SEC ticker list
#1295 of the 3,000 companies we track

Five-year financial highlights

Full-year figures from Oruka Therapeutics, Inc.’s annual reports, as tagged in XBRL and published by the SEC. Amounts are in U.S. dollars; the fiscal year is named for the calendar year in which it ends.

Revenue
$0FY2020$0FY2021$0FY2022$0FY2023n/aFY2025
Net income
-$9.7MFY2020-$19.3MFY2021-$9.9MFY2022-$5.3MFY2023-$105.4MFY2025
ORKA annual results
ItemFY2020
ended Dec 31, 2020		FY2021
ended Dec 31, 2021		FY2022
ended Dec 31, 2022		FY2023
ended Dec 31, 2023		FY2025
ended Dec 31, 2025
Revenue$0$0$0$0—
Net income-$9.7M-$19.3M-$9.9M-$5.3M-$105.4M
Diluted EPS-$2.07-$1.39-$0.69-$0.37—
Total assets$50.4M$54.9M$43.1M$37.9M$488.6M
Cash and equivalents$49.1M$53.4M$42.4M$37.4M$46.9M

XBRL tags used: revenue = Revenues; netIncome = NetIncomeLoss; assets = Assets; eps = EarningsPerShareBasicAndDiluted; cash = CashAndCashEquivalentsAtCarryingValue. EPS is shown as originally reported for each year and may not be adjusted for later stock splits. A dash means the company did not report that item in a form we could match.

How to read these numbers

Revenue is the money a company brings in from selling its products and services; net income is what is left after all expenses, interest and taxes. Diluted EPS spreads net income across every share that could exist if options and convertible securities were exercised. Total assets and cash are balance-sheet figures measured on the last day of the fiscal year. For the full story — segment results, one-time charges, guidance — read Management’s Discussion and Analysis in the Form 10-K.

Latest key reports

The most recent filing of each major report type, even if it falls outside the 40 newest filings below.

ORKA latest annual, quarterly, current and proxy reports
FiledFormWhat it isOriginal
Mar 12, 202610-KANNUAL REPORT· period Dec 31, 2025Document · Index
Aug 10, 202610-QQUARTERLY REPORT· period Jun 30, 2026Document · Index
Oct 26, 20268-KRegulation FD disclosure; Other events· period Oct 26, 2026Document · Index
Apr 17, 2026DEF 14APROXY STATEMENT· period Jun 2, 2026Document · Index

Recent SEC filings

The 40 newest documents filed by or about Oruka Therapeutics, Inc., by form type:

4 ×19144 ×98-K ×3SCHEDULE 13G ×2SCHEDULE 13G/A ×23 ×1424B5 ×1EFFECT ×1S-3 ×110-Q ×1
ORKA recent filings
FiledFormWhat it isOriginal
Oct 26, 20268-KRegulation FD disclosure; Other events· period Oct 26, 2026Document · Index
Oct 20, 20264STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES· period Oct 20, 2026Document · Index
Oct 15, 2026144Notice of proposed sale of securitiesDocument · Index
Oct 15, 20264STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES· period Oct 15, 2026Document · Index
Oct 13, 2026144Notice of proposed sale of securitiesDocument · Index
Oct 13, 20264STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES· period Oct 12, 2026Document · Index
Oct 2, 20264STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES· period Oct 1, 2026Document · Index
Oct 1, 2026144Notice of proposed sale of securitiesDocument · Index
Sep 21, 2026144Notice of proposed sale of securitiesDocument · Index
Sep 21, 20264STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES· period Sep 21, 2026Document · Index
Sep 21, 20264STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES· period Sep 21, 2026Document · Index
Sep 15, 20264STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES· period Sep 15, 2026Document · Index
Sep 15, 20264STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES· period Sep 11, 2026Document · Index
Sep 15, 20264STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES· period Sep 15, 2026Document · Index
Sep 15, 20264STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES· period Sep 15, 2026Document · Index
Sep 15, 20264STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES· period Sep 15, 2026Document · Index
Sep 1, 2026144Notice of proposed sale of securitiesDocument · Index
Sep 1, 2026144Notice of proposed sale of securitiesDocument · Index
Sep 1, 20264STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES· period Sep 1, 2026Document · Index
Sep 1, 20264STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES· period Sep 1, 2026Document · Index
Aug 28, 2026424B5PROSPECTUSDocument · Index
Aug 27, 2026EFFECTEFFECTDocument · Index
Aug 25, 20264STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES· period Aug 24, 2026Document · Index
Aug 25, 20263INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES· period Aug 24, 2026Document · Index
Aug 24, 20268-KDirector or officer change· period Aug 24, 2026Document · Index
Aug 21, 2026S-3REGISTRATION STATEMENTDocument · Index
Aug 17, 20264STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES· period Aug 17, 2026Document · Index
Aug 14, 2026144Notice of proposed sale of securitiesDocument · Index
Aug 14, 2026SCHEDULE 13GPassive beneficial ownership report (over 5%)Document · Index
Aug 14, 2026SCHEDULE 13G/APassive beneficial ownership report (over 5%)Document · Index
Aug 14, 20264STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES· period Aug 14, 2026Document · Index
Aug 14, 20264STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES· period Aug 13, 2026Document · Index
Aug 14, 2026SCHEDULE 13G/APassive beneficial ownership report (over 5%)Document · Index
Aug 12, 2026SCHEDULE 13GPassive beneficial ownership report (over 5%)Document · Index
Aug 10, 202610-QQUARTERLY REPORT· period Jun 30, 2026Document · Index
Aug 10, 20268-KResults of operations· period Aug 10, 2026Document · Index
Jul 15, 2026144Notice of proposed sale of securitiesDocument · Index
Jul 15, 20264STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES· period Jul 15, 2026Document · Index
Jul 13, 2026144Notice of proposed sale of securitiesDocument · Index
Jul 13, 20264STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES· period Jul 13, 2026Document · Index

Insider filing activity

55 Form 4 filings appear in Oruka Therapeutics, Inc.’s EDGAR record between Oct 28, 2025 and our last refresh. Most are reports by the company’s own directors, officers and 10% owners, but EDGAR also lists a Form 4 under a company when the company itself is the insider — for example, when it owns more than 10% of another public company. Foreign private issuers’ own insiders generally do not file Form 4. A high count is not by itself a signal: many Form 4s report routine stock awards, tax withholding or sales under pre-arranged Rule 10b5-1 plans. Open each filing to see the transaction code, share count and price. What a Form 4 shows.

Other companies in Pharmaceutical Preparations

All 194 companies in Pharmaceutical Preparations· Companies headquartered in California

On Amazon

Popular tools for investors

As an Amazon Associate I earn from qualifying purchases.

Electronics Plaud Note Pro AI Voice Recorder An AI voice recorder that turns earnings calls and meetings into notes. View on Amazon → Electronics Amazon Kindle Paperwhite Signature Edition 32GB Read investing classics and long reports without eye strain. View on Amazon → Electronics Apple 2026 MacBook Air 13-inch Laptop A lightweight laptop for spreadsheets and filing research. View on Amazon →

Source

  • U.S. Securities and Exchange Commission, EDGAR submissions for CIK 0000907654 and XBRL company facts. Oruka Therapeutics, Inc. on EDGAR.
  • Snapshot updated Oct 27, 2026, 11:27 PM EDT. The SEC does not endorse OpenFilings. Company names and tickers are used only to identify the filer; no logos are shown.

Not investment advice. This page summarizes public SEC filings for information only. Figures may contain errors or omissions; confirm everything in the original filing before relying on it.